I think the company relying on the NASDAQ is a risky move in itself too. TLX decided to pull the pin on their dual listing due to unfavourable conditions and they didn't even need the money. and were in a much better position than AVR is. I hope there is light at the end of the tunnel, but it seems like we're not even close to the end.
Clinical trials, page-12
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.800(6.06%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $13.08 | $14.00 | $12.84 | $202.5K | 15.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 88 | $13.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1109 | 2 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |